[go: up one dir, main page]

MX2023001296A - Composiciones y metodos para tratar enfermedades y trastornos. - Google Patents

Composiciones y metodos para tratar enfermedades y trastornos.

Info

Publication number
MX2023001296A
MX2023001296A MX2023001296A MX2023001296A MX2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A
Authority
MX
Mexico
Prior art keywords
disorders
methods
compositions
treating diseases
diseases
Prior art date
Application number
MX2023001296A
Other languages
English (en)
Inventor
Roemeling Reinhard Von
Robert Martell
Elizabeth Martinez
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of MX2023001296A publication Critical patent/MX2023001296A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con métodos para tratar ciertas enfermedades y trastornos (p. ej., enfermedades y trastornos asociados a IRAK4). La presente descripción se relaciona también con composiciones farmacéuticas que comprenden compuestos para tratar las enfermedades y trastornos mencionados anteriormente.
MX2023001296A 2020-08-03 2021-04-30 Composiciones y metodos para tratar enfermedades y trastornos. MX2023001296A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060413P 2020-08-03 2020-08-03
US202063115312P 2020-11-18 2020-11-18
PCT/US2021/030192 WO2022031330A1 (en) 2020-08-03 2021-04-30 Compositions and methods for treating diseases and disorders

Publications (1)

Publication Number Publication Date
MX2023001296A true MX2023001296A (es) 2023-02-22

Family

ID=80117618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001296A MX2023001296A (es) 2020-08-03 2021-04-30 Composiciones y metodos para tratar enfermedades y trastornos.

Country Status (12)

Country Link
US (1) US20230310444A1 (es)
EP (1) EP4188368A4 (es)
JP (1) JP2023537477A (es)
KR (1) KR20230048358A (es)
CN (1) CN116419752A (es)
AU (1) AU2021321350A1 (es)
BR (1) BR112023001861A2 (es)
CA (1) CA3188171A1 (es)
CU (1) CU20230009A7 (es)
IL (1) IL300310A (es)
MX (1) MX2023001296A (es)
WO (1) WO2022031330A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3466955T1 (sl) 2014-01-13 2021-05-31 Aurigene Discovery Technologies Limited Postopek za pripravo derivatov oksazolo(4,5-B)piridina in tiazolo(4,5-B)piridina kot inhibitorjev IRAK4 za zdravljenje raka
JP2024516353A (ja) 2021-04-08 2024-04-15 キュリス，インコーポレイテッド がんの治療のための併用療法
WO2023172640A1 (en) * 2022-03-08 2023-09-14 X4 Pharmaceuticals, Inc. Treatments for single-mutant waldenström's macroglobulinemia
WO2024027750A1 (en) * 2022-08-02 2024-02-08 Beigene Switzerland Gmbh Methods of treating pulmonary hypertension using btk inhibitors
WO2025208000A1 (en) * 2024-03-29 2025-10-02 Curis, Inc. Methods of treating cancer in patients with altered protein expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3466955T1 (sl) * 2014-01-13 2021-05-31 Aurigene Discovery Technologies Limited Postopek za pripravo derivatov oksazolo(4,5-B)piridina in tiazolo(4,5-B)piridina kot inhibitorjev IRAK4 za zdravljenje raka
CA2984259C (en) * 2015-04-30 2024-02-13 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
MX389825B (es) * 2017-03-31 2025-03-20 Aurigene Discovery Tech Ltd Compuestos y composiciones para tratar trastornos hematologicos.
HUE067356T2 (hu) * 2017-10-31 2024-10-28 Curis Inc IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
JP2024516353A (ja) * 2021-04-08 2024-04-15 キュリス，インコーポレイテッド がんの治療のための併用療法

Also Published As

Publication number Publication date
CU20230009A7 (es) 2023-09-07
CN116419752A (zh) 2023-07-11
AU2021321350A1 (en) 2023-03-16
BR112023001861A2 (pt) 2023-03-07
EP4188368A1 (en) 2023-06-07
CA3188171A1 (en) 2022-02-10
WO2022031330A1 (en) 2022-02-10
EP4188368A4 (en) 2024-09-04
JP2023537477A (ja) 2023-09-01
US20230310444A1 (en) 2023-10-05
IL300310A (en) 2023-04-01
KR20230048358A (ko) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2022016415A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
MX2024013215A (es) Compuestos para inhibir kif18a
WO2019224790A3 (en) Prodrugs of fulvestrant
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12022550497A1 (en) Perk inhibiting compounds
WO2021100029A3 (en) Prodrugs of fulvestrant
PH12019500198A1 (en) Compounds and compositions and uses thereof
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases